Search research articles
Contact Us
Filters
Showing results (51-60 of 75) with videos related to
Page
of 8
Sort By:
Molecular Pharmaceutics
|
August 18, 2017
In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole
Bart Hens, Shriram M Pathak, Amitava Mitra, et al.
Molecular Cancer Therapeutics
|
March 25, 2026
Farnesyl transferase inhibitor KO-2806 (darlifarnib) enhances the anti-tumor activity of tyrosine kinase inhibitors in RCC
Jovylyn G Gasendo, Stacia Chan, Hetika V Patel, et al.
Journal of Agricultural and Food Chemistry
|
March 29, 2016
Proteomic Investigation of Rhizoctonia solani AG 4 Identifies Secretome and Mycelial Proteins with Roles in Plant Cell Wall Degradation and Virulence
Dilip K Lakshman, Daniel P Roberts, Wesley M Garrett, et al.
Clinical Pharmacology and Therapeutics
|
July 11, 2024
New Horizons of Model Informed Drug Development in Rare Diseases Drug Development
Amitava Mitra, Nessy Tania, Mariam A Ahmed, et al.
Clinical Pharmacology in Drug Development
|
January 19, 2026
A Thorough QT Study to Assess the Effects of Milvexian on Cardiac Repolarization in Healthy Participants
Peter Zannikos, JongHanne Park, Anna Dari, et al.
Clinical Pharmacology and Therapeutics
|
June 14, 2023
Model-Informed Approaches and Innovative Clinical Trial Design for Adeno-Associated Viral Vector-Based Gene Therapy Product Development: A White Paper
Amitava Mitra, Mariam A Ahmed, Rajesh Krishna, et al.
Pharmaceutics
|
September 28, 2021
PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5'-Diphospho-glucuronosyltransferase Substrates
Micaela B Reddy, Michael B Bolger, Grace Fraczkiewicz, et al.
Cancer Research
|
February 9, 2026
The farnesyl transferase inhibitor darlifarnib (KO-2806) re-sensitizes relapsing tumors to RAS inhibition
Hetika Vora Patel, Alison Elizabeth Smith, Stacia Chan, et al.
Clinical Pharmacology and Therapeutics
|
August 16, 2024
Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers
Mariam A Ahmed, Rajesh Krishna, Noha Rayad, et al.
Molecular Pharmaceutics
|
April 11, 2024
Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report
Claire Mackie, Sumit Arora, Paul Seo, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 75) with videos related to
Sort By:
Page
of 8
Molecular Pharmaceutics
|
August 18, 2017
In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole
Bart Hens, Shriram M Pathak, Amitava Mitra, et al.
Molecular Cancer Therapeutics
|
March 25, 2026
Farnesyl transferase inhibitor KO-2806 (darlifarnib) enhances the anti-tumor activity of tyrosine kinase inhibitors in RCC
Jovylyn G Gasendo, Stacia Chan, Hetika V Patel, et al.
Journal of Agricultural and Food Chemistry
|
March 29, 2016
Proteomic Investigation of Rhizoctonia solani AG 4 Identifies Secretome and Mycelial Proteins with Roles in Plant Cell Wall Degradation and Virulence
Dilip K Lakshman, Daniel P Roberts, Wesley M Garrett, et al.
Clinical Pharmacology and Therapeutics
|
July 11, 2024
New Horizons of Model Informed Drug Development in Rare Diseases Drug Development
Amitava Mitra, Nessy Tania, Mariam A Ahmed, et al.
Clinical Pharmacology in Drug Development
|
January 19, 2026
A Thorough QT Study to Assess the Effects of Milvexian on Cardiac Repolarization in Healthy Participants
Peter Zannikos, JongHanne Park, Anna Dari, et al.
Clinical Pharmacology and Therapeutics
|
June 14, 2023
Model-Informed Approaches and Innovative Clinical Trial Design for Adeno-Associated Viral Vector-Based Gene Therapy Product Development: A White Paper
Amitava Mitra, Mariam A Ahmed, Rajesh Krishna, et al.
Pharmaceutics
|
September 28, 2021
PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5'-Diphospho-glucuronosyltransferase Substrates
Micaela B Reddy, Michael B Bolger, Grace Fraczkiewicz, et al.
Cancer Research
|
February 9, 2026
The farnesyl transferase inhibitor darlifarnib (KO-2806) re-sensitizes relapsing tumors to RAS inhibition
Hetika Vora Patel, Alison Elizabeth Smith, Stacia Chan, et al.
Clinical Pharmacology and Therapeutics
|
August 16, 2024
Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers
Mariam A Ahmed, Rajesh Krishna, Noha Rayad, et al.
Molecular Pharmaceutics
|
April 11, 2024
Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report
Claire Mackie, Sumit Arora, Paul Seo, et al.
Page
of 8